BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 9155159)

  • 1. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
    Furukawa M; Harada T; Tanaka T; Kuwano M
    Nihon Rinsho; 1997 May; 55(5):1096-102. PubMed ID: 9155159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
    Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M
    Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA topoisomerase-targeting antitumor agents and drug resistance.
    Takano H; Kohno K; Matsuo K; Matsuda T; Kuwano M
    Anticancer Drugs; 1992 Aug; 3(4):323-30. PubMed ID: 1330080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S; Riou G
    Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
    Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
    Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerase inhibitors.
    Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
    Cancer Chemother Biol Response Modif; 1994; 15():67-86. PubMed ID: 7779607
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
    Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
    Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].
    Matsumoto Y; Takano H; Nagao S; Iglesias A; Fojo T
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2265-9. PubMed ID: 9422071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines].
    Matsumoto Y; Morisaki K; Kunishio K; Nagao S; Takano H; Fojo T
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1145-9. PubMed ID: 9679576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha.
    Kuriyama M; Tsutsui K; Tsutsui K; Ono Y; Tamiya T; Matsumoto K; Furuta T; Ohmoto T
    Neurol Med Chir (Tokyo); 1997 Sep; 37(9):655-61; discussion 661-2. PubMed ID: 9330528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
    Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a CPT-11-resistant human ovarian cancer cell line.
    Kijima T; Kubota N; Nishio K
    Anticancer Res; 1994; 14(3A):799-803. PubMed ID: 8074481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
    Hirohashi Y; Hidaka K; Sato S; Kuwano M; Kohno K; Hisatsugu T
    Jpn J Cancer Res; 1995 Nov; 86(11):1097-105. PubMed ID: 8567402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
    Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
    Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
    Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
    Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.